SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance
1 references·0 citing·5 second hop
The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance (2023)The Accelerated Approval Program for Canc…Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study (2021)Regulatory and clinical conse…A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics (2018)Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval (2019)Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward (2022)Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021 (2022)Current landscape of innovative drug development and regulatory support in China (2025)
this work references cited by second hop

References

  • 2021Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study112 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work